Effect of Amifostine in Head and Neck Cancer Patients Treated with Radiotherapy: A Systematic Review and Meta-Analysis Based on Randomized Controlled Trials
Background Amifostine is the most clinical used chemical radioprotector, but its effect in patients treated with radiation is not consistent. Methods By searching Medline, CENTRAL, EMBASE, ASCO, ESMO, and CNKI databases, the published randomized controlled trials (RCTs) about the efficacy of amifostine in HNSCC patients treated with radiotherapy were collected. The pooled efficacy and side effects of this drug were calculated by RevMan software. Results Seventeen trials including a total of 1167 patients (604 and 563 each arm) were analyzed in the meta-analysis. The pooled data showed that the use of amifostine significantly reduce the risk of developing Grade3–4 mucositis (relative risk [RR],0.72; 95% confidence interval [CI],0.54–0.95; p<0.00001), Grade 2–4 acute xerostomia (RR,0.70; 95%CI,0.52–0.96; p = 0.02), or late xerostomia (RR,0.60; 95%CI,0.49–0.74; p<0.00001) and Grade 3–4 dysphagia (RR,0.39; 95%CI,0.17–0.92; p = 0.03). However, subgroup analysis demonstrated that no statistically significant reduction of Grade3–4 mucositis (RR,0.97; 95% CI,0.74–1.26; p = 0.80), Grade 2–4 acute xerostomia (RR,0.35; 95%CI,0.02–5.44; p = 0.45), or late xerostomia (RR,0.40; 95%CI,0.13–1.24; p = 0.11) and Grade 3–4 dysphagia (RR,0.23; 95%CI,0.01–4.78; p = 0.35) was observed in patients treated with concomitant chemoradiotherapy. Compared with placebo or observation, amifostine does not show tumor protective effect in complete response (RR,1.02; 95%CI,0.89–1.17; p = 0.76) and partial response (RR,0.90; 95%CI, 0.56–1.44; p = 0.66). For the hematologic side effect, no statistical difference of Grade 3–4 leucopenia (RR,0.60; 95%CI,0.35–1.05; p = 0.07), anemia (RR,0.80; 95%CI, 0.42–1.53; p = 0.50) and thrombocytopenia (RR,0.43; 95%CI,0.16–1.15; p = 0.09) were found between amifostine and control groups. The most common amifostine related side effects were nausea, emesis, hypotension and allergic with an average incidence rate (Grade 3–4) of 5%, 6%, 4% and 4% respectively. Conclusion This systematic review showed that amifostine significantly reduce the serious mucositis, acute/late xerastomia and dysphagia without protection of the tumor in HNSCC patients treated with radiotherapy. And the toxicities of amifostine were generally acceptable.
References
[1]
Toledano I, Graff P, Serre A, Boisselier P, Bensadoun RJ, et al. (2012) Intensity-modulated radiotherapy in head and neck cancer: results of the prospective study GORTEC 2004-03. Radiother Oncol 103(1): 57–62. doi: 10.1016/j.radonc.2011.12.010
[2]
Cvek J, Kubes J, Skacelikova E, Otahal B, Kominek P, et al. (2012) Hyperfractionated accelerated radiotherapy with concomitant integrated boost of 70–75 Gy in 5 weeks for advanced head and neck cancer: A phase I does escalation study. Strahlenther Onkol 188(8): 666–670. doi: 10.1007/s00066-012-0128-x
[3]
Brizel DM, Wasserman TH, Henke M, Strnad V, Rudat V, et al. (2000) Phase III randomized trial of amifostine as a radioprotector in head and neck cancer. J Clin Oncol 18(19): 3339–3345.
[4]
Koukourakis MI (2002) Amifostine in clinical oncology: current use and future applications. Anticancer Drugs 13(3): 181–209. doi: 10.1097/00001813-200203000-00001
[5]
Veerasarn V, Phromratanapongse P, Suntornpong N, Lorvidhaya V, Sukthomya V, et al. (2006) Effect of Amifostine to prevent radiotherapy-induced acute and late toxicity in head and neck cancer patients who had normal or mild impaired salivary gland function. J Med Assoc Thai 89(12): 2056–2067. doi: 10.1016/s1359-6349(03)90935-9
[6]
Buentzel J, Micke O, Adamietz IA, Monnier A, Glatzel M, et al. (2006) Intravenous amifostine during chemoradiotherapy for head-and-neck cancer: Arandomized placebo-controlled phase III study. Int J Radiat Oncol Biol Phys 64(3): 684–691. doi: 10.1016/j.ijrobp.2005.08.005
[7]
Jellema AP, Slotman BJ, Muller MJ, Leemans CR, Smeele LE, et al. (2006) Radiotherapy alone, versus radiotherapy with amifostine 3 times weekly, versus radiotherapy with amifostine 5 times weekly: A prospective randomized study in squamous cell head and neck cancer. Cancer 107(3): 544–553. doi: 10.1002/cncr.22020
[8]
Koukourakis MI (2003) Amifostine: is there evidence of tumor protection? Semin Oncol 30 6 Suppl 1818–30. doi: 10.1053/j.seminoncol.2003.11.014
[9]
Higgins JP, Green S (2008) Cochrane Handbook for Systematic Reviews of Interventions updated March 2011 John Wiley & Sons, Available: http://www.cochrane-handbook.org/.Accessed: 2011 DEC 12.
[10]
Cox JD, Stetz J, Pajak TF (1995) Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the EuropeanOrganization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys 31(5): 1341–1346. doi: 10.1016/0360-3016(95)00060-c
[11]
DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7(3): 177–188. doi: 10.1016/0197-2456(86)90046-2
Egger M, Davey SG, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315(7109): 629–634. doi: 10.1136/bmj.315.7109.629
[14]
Wasserman TH, Brizel DM, Henke M, Monnier A, Eschwege F, et al. (2005) Influence of intravenous amifostine on xerostomia, tumor control, and survival after radiotherapy for head-and- neck cancer: 2-year follow-up of a prospective, randomized, phase III trial. Int J Radiat Oncol Biol Phys 63(4): 985–990. doi: 10.1016/j.ijrobp.2005.07.966
[15]
Bennett CL, Lane D, Stinson T, Glatzel M, Buntzel J (2001) Economic analysis of amifostine as adjunctive support for patients with advanced head and neck cancer: preliminary results from a randomized phase II clinical trial from Germany. Cancer Invest 19(2): 107–113. doi: 10.1081/cnv-100000145
[16]
Buntzel J, Schuth J, Kuttner K, Glatzel M (1998) Radiochemotherapy with amifostine cytoprotection for head and neck cancer. Support Care Cancer 6(2): 155–160. doi: 10.1007/s005200050150
[17]
Anne PR, Machtay M, Rosenthal DI, Brizel DM, Morrison WH, et al. (2007) A Phase II trial of subcutaneous amifostine and radiation therapy in patients with head-and-neck cancer. Int J Radiat Oncol Biol Phys 67(2): 445–452. doi: 10.1016/j.ijrobp.2006.08.044
[18]
Abitbol A, Abdel-Wahab M, Harvey M, Lewin A, Troner M, et al. (2005) Phase II study of tolerance and efficacy of hyperfractionated radiation therapy and 5-fluorouracil, cisplatin, and paclitaxel (taxol) and amifostine (ethyol) in head and neck squamous cell carcinomas: A-3 protocol. Am J Clin Oncol 28(5): 449–455. doi: 10.1097/01.coc.0000164010.12931.cd
[19]
Trog D, Bank P, Wendt TG, Koscielny S, Beleites E (1999) Daily amifostine given concomitantly to chemoradiation in head and neck cancer. Apilot study. Strahlenther Onkol 175(9): 444–449. doi: 10.1007/s000660050034
[20]
Rosenthal DI, Chambers MS, Weber RS, Eisbruch A (2004) A phase II study to assess the efficacy of amifostine for submandibular/sublingual salivary sparing during the treatment of head and neck cancer with intensity modulated radiation therapy for parotid salivary sparing. Semin Oncol 31 6 Suppl 1825–28. doi: 10.1053/j.seminoncol.2004.12.008
[21]
Zoberi I, Wasserman TH, Chao KS (2002) A prospective, nonrandomized study of the impact of amifostine on subsequent hypothyroidism in irradiated patients with head and neck cancers. Semin Radiat Oncol 12 1 Suppl 114–17. doi: 10.1053/srao.2002.31357
[22]
Suntharalingam M, Jaboin J, Taylor R, Wolf J, Banglore M, et al. (2004) The evaluation of amifostine for mucosal protection in patients with advanced loco-regional squamous cell carcinomas of the head and neck (SCCHN) treated with concurrent weekly carboplatin, paclitaxel, and daily radiotherapy (RT). Semin Oncol 31 6 Suppl 182–7. doi: 10.1053/j.seminoncol.2005.02.001
[23]
Thorstad WL, Haughey B, Chao KS (2003) Pilot study of subcutaneous amifostine in patients undergoing postoperative intensity modulated radiation therapy for head and neck cancer: preliminary data. Semin Oncol 30 6 Suppl 1896–100. doi: 10.1053/j.seminoncol.2003.11.020
[24]
Vacha P, Fehlauer F, Mahlmann B, Marx M, Hinke A, et al. (2003) Randomized phase III trial of postoperative radiochemotherapy +/？ amifostine in head and neck cancer. Is there evidence for radioprotection. Strahlenther Onkol 179(6): 385–389.
[25]
Wasserman T, Mackowiak JI, Brizel DM, Oster W, Zhang J, et al. (2000) Effect of amifostine on patient assessed clinical benefit in irradiated head and neck cancer. Int J Radiat Oncol Biol Phys 48(4): 1035–1039. doi: 10.1016/s0360-3016(00)00735-5
[26]
Thorstad WL, Chao KS, Haughey B (2004) Toxicity and compliance of subcutaneous amifostine in patients undergoing postoperative intensity-modulated radiation therapy for head and neck cancer. Semin Oncol 31 6 Suppl 188–12. doi: 10.1053/j.seminoncol.2004.12.005
[27]
Chao KS, Ozyigit G, Thorsdad WL (2003) Toxicity profile of intensity-modulated radiation therapy for head and neck carcinoma and potential role of amifostine. Semin Oncol 30 6 Suppl 18101–108. doi: 10.1053/j.seminoncol.2003.11.009
[28]
Machtay M, Rosenthal DI, Chalian AA, Lustig R, Hershock D, et al. (2004) Pilot study of postoperative reirradiation, chemotherapy, and amifostine after surgical salvage for recurrent head-and-neck cancer. Int J Radiat Oncol Biol Phys 59(1): 72–77. doi: 10.1016/j.ijrobp.2003.10.056
[29]
Bardet E, Martin L, Calais G, Tuchais C, Bourhis J, et al. (2002) Preliminary data of the GORTEC 2000-02 phase III trial comparing intravenous and subcutaneous administration of amifostine for head and neck tumors treated by external radiotherapy. Semin Oncol 29 6 Suppl 1957–60. doi: 10.1053/sonc.2002.37348
[30]
Anacak Y, Kamer S, Haydaroglu A (2005) Daily subcutaneous amifostine administration during irradiation of pediatric head and neck cancers. Pediatr Blood Cancer 48(5): 579–581. doi: 10.1002/pbc.20740
[31]
Amrein PC, Clark JR, Supko JG, Fabian RL, Wang CC, et al. (2005) Phase I trial and pharmacokinetics of escalating doses of paclitaxel and concurrent hyperfractionated radiotherapy with or without amifostine in patients with advanced head and neck carcinoma. Cancer 104(7): 1418–1827. doi: 10.1002/cncr.21312
[32]
Antonadou D, Pepelassi M, Synodinou M, Puglisi M, Throuvalas N (2002) Prophylactic use of amifostine to prevent radiochemotherapy-induced mucositis and xerostomia in head-and-neck cancer. Int J Radiat Oncol Biol Phys 52(3): 739–747. doi: 10.1016/s0360-3016(01)02683-9
[33]
Bourhis J, De Crevoisier R, Abdulkarim B, Deutsch E, Lusinchi A, et al. (2000) A randomized study of very accelerated radiotherapy with and without amifostine in head and neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys 46(5): 1105–1108. doi: 10.1016/s0360-3016(99)00532-5
[34]
Braaksma M, van Agthoven M, Nijdam W, Uyl-de GC, Levendag P (2005) Costs of treatment intensification for head and neck cancer: concomitant chemoradiation randomised for radioprotection with amifostine. Eur J Cancer 41(14): 2102–2111. doi: 10.1016/j.ejca.2005.05.012
[35]
Buntzel J, Kuttner K, Frohlich D, Glatzel M (1998) Selective cytoprotection with amifostine in concurrent radiochemotherapy for head and neck cancer. Ann Oncol 9(5): 505–509. doi: 10.1007/s005200050150
[36]
Haddad R, Sonis S, Posner M, Wirth L, Costello R, et al. (2009) Randomized phase 2 study of concomitant chemoradiotherapy using weeklycarboplatin/paclitaxel carboplatin/paclitaxel with or without daily subcutaneous amifostine in patients with locally advanced head and neck cancer. Cancer 115(19): 4514–4523. doi: 10.1002/cncr.24525
[37]
Peng LH, Sun Y, Zhang XL, Zhang Q, Fu S (2006) Efficacy of Amifostine on Patients with Head and Neck Squamous Cell Carcinomas Undergoing Radiation Therapy and Chemotherapy. China Pharmacy 17(5): 1166–1168.
[38]
Fan ZG, Lin HX, Liu ZQ, He QH, Zhang SL, et al. (2011) Protective effect of amifostine for mucositis and xerostomia in nasopharyngeal carcinoma patients treated with irradiation. Military Medical Journal of Southeast China 13(2): 146–148.
[39]
Koukourakis MI, Kyrias G, Kakolyris S, Kouroussis C, Frangiadaki C (2000) Subcutaneous administration of amifostine during fractionated radiotherapy: a randomized phase II study. J Clin Oncol 18(11): 2226–2233.
[40]
Zhang N, Xu LJ, Ding JY (2010) Protection effect of amifostine on oral mucosa in patients treated with concurrent chemoradiation. Chin J Prim Med Pharm 17(5): 668–669.
[41]
Jiang F, Chen XZ, Wang FZ (2009) Effects of amifostine on nasopharyngeal patients treated with chemoradiotherapy. Chin J Radiol Med Prot 29(6): 612–613.
[42]
Yu DS, Zhao W, Wu XL, Huang ZQ, Huang RB (2009) Amifostine in Prevention of Radiation induced Xerostomia. Journal of Sun Yatsen University(Medical Sciences) 30(4S): : 86–87;95.
[43]
He XY, Hu CS, Wu YR (2004) Radioprotective Effect of Amifostine in Nasopharyngeal Carcinoma. Fudan Univ J Med Sci 31(1): 53–58.
[44]
Anne PR, Curran WJ Jr (2002) A phase II trial of subcutaneous amifostine and radiation therapy in patients with head and neck cancer. Semin Radiat Oncol 12 1 Suppl 118–19. doi: 10.1053/srao.2002.31358
[45]
Jemal A, Bray F (2011) Center MM, Ferlay J, Ward E, et al (2011) Global cancer statistics. CA Cancer J Clin 61(2): 69–90. doi: 10.3322/caac.20107
[46]
Brizel DM, Overgaard J (2003) Does amifostine have a role in chemoradiation treatment. Lancet Oncol 4(6): 378–381. doi: 10.1016/s1470-2045(03)01132-x
[47]
Bourhis J, Blanchard P, Maillard E, Brizel DM, Movsas B, et al. (2011) Effect of amifostine on survival among patients treated with radiotherapy: meta-analysis of individual patient data. J Clin Oncol 29(18): 2590–2597. doi: 10.1200/jco.2010.33.1454
[48]
Trinquart L, Abbe A, Ravaud P (2012) Impact of reporting bias in network meta-analysis of antidepressant placebo-controlled trials. PLOS ONE 7(4): e35219. doi: 10.1371/journal.pone.0035219
